TW202504901A - 咪唑并嗒嗪及咪唑并吡啶化合物及其用途 - Google Patents
咪唑并嗒嗪及咪唑并吡啶化合物及其用途 Download PDFInfo
- Publication number
- TW202504901A TW202504901A TW113128182A TW113128182A TW202504901A TW 202504901 A TW202504901 A TW 202504901A TW 113128182 A TW113128182 A TW 113128182A TW 113128182 A TW113128182 A TW 113128182A TW 202504901 A TW202504901 A TW 202504901A
- Authority
- TW
- Taiwan
- Prior art keywords
- alkyl
- membered
- independently selected
- alkylene
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782994P | 2018-12-20 | 2018-12-20 | |
| US62/782,994 | 2018-12-20 | ||
| US201962935891P | 2019-11-15 | 2019-11-15 | |
| US62/935,891 | 2019-11-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202504901A true TW202504901A (zh) | 2025-02-01 |
Family
ID=69467674
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW113128182A TW202504901A (zh) | 2018-12-20 | 2019-12-19 | 咪唑并嗒嗪及咪唑并吡啶化合物及其用途 |
| TW108146732A TWI852968B (zh) | 2018-12-20 | 2019-12-19 | 咪唑并嗒嗪及咪唑并吡啶化合物及其用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108146732A TWI852968B (zh) | 2018-12-20 | 2019-12-19 | 咪唑并嗒嗪及咪唑并吡啶化合物及其用途 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11459329B2 (enExample) |
| EP (1) | EP3898627A1 (enExample) |
| JP (2) | JP7414827B2 (enExample) |
| KR (1) | KR20210116488A (enExample) |
| CN (2) | CN120208959A (enExample) |
| AU (1) | AU2019401649B2 (enExample) |
| BR (1) | BR112021011948A2 (enExample) |
| CA (1) | CA3124088A1 (enExample) |
| CL (1) | CL2021001656A1 (enExample) |
| CO (1) | CO2021008117A2 (enExample) |
| CR (1) | CR20210336A (enExample) |
| EC (1) | ECSP21044843A (enExample) |
| IL (2) | IL318278A (enExample) |
| MA (1) | MA54551A (enExample) |
| MX (1) | MX2021007426A (enExample) |
| PE (1) | PE20220277A1 (enExample) |
| PH (1) | PH12021551446A1 (enExample) |
| SG (1) | SG11202106582YA (enExample) |
| TW (2) | TW202504901A (enExample) |
| WO (1) | WO2020132197A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3124088A1 (en) | 2018-12-20 | 2020-06-25 | Incyte Corporation | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| CA3184811A1 (en) | 2020-06-12 | 2021-12-16 | Incyte Corporation | Imidazopyridazine compounds with activity as alk2 inhibitors |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| CN118119619A (zh) * | 2021-10-18 | 2024-05-31 | 上海美悦生物科技发展有限公司 | Sik抑制剂及其组合物、制备方法和用途 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6355653B1 (en) | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
| DE60110219T2 (de) | 2000-05-26 | 2006-03-09 | Schering Corp. | Adenosin a2a rezeptor antagonisten |
| KR100786927B1 (ko) | 2000-06-28 | 2007-12-17 | 스미스클라인비이참피이엘시이 | 습식 분쇄방법 |
| AR038366A1 (es) | 2001-11-30 | 2005-01-12 | Schering Corp | Compuestos de 1,2,4-triazolo [1,5-c] pirimidinas sustituidas, antagonistas del receptor de adenosina a2a, composiciones farmaceuticas, el uso de dichos compuestos para la manufactura de un medicamento para el tratamiento de enfermedades del sistema nervioso central y un kit que comprende combinacion |
| WO2004092177A1 (en) | 2003-04-09 | 2004-10-28 | Biogen Idec Ma Inc. | Triazolopyrazines and methods of making and using the same |
| JP2005343889A (ja) | 2004-05-06 | 2005-12-15 | Taisho Pharmaceut Co Ltd | イミダゾピリジン誘導体 |
| PT1812440E (pt) | 2004-11-04 | 2011-01-25 | Vertex Pharma | Pirazolo[1,5-a]pirimidinas úteis enquanto inibidores de proteínas cinases |
| RS54510B1 (sr) * | 2006-11-22 | 2016-06-30 | Incyte Holdings Corporation | Imidazotriazini i imidazopirimidini kao inhibitori kinaze |
| HUP0700395A2 (en) | 2007-06-07 | 2009-03-02 | Sanofi Aventis | Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates |
| KR20150036210A (ko) | 2007-06-13 | 2015-04-07 | 인사이트 코포레이션 | 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염 |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| ATE522249T1 (de) * | 2007-07-26 | 2011-09-15 | Novartis Ag | Organische verbindungen |
| AR068877A1 (es) | 2007-10-17 | 2009-12-09 | Novartis Ag | Derivados heterociclicos de imidazol |
| JP2012533545A (ja) | 2009-07-14 | 2012-12-27 | ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド | 肝臓の増殖を増大させる方法 |
| PE20130216A1 (es) | 2010-05-21 | 2013-02-27 | Incyte Corp | Formulacion topica para un inhibidor de jak |
| CA2806655A1 (en) * | 2010-07-28 | 2012-02-02 | Bayer Intellectual Property Gmbh | Substituted imidazo[1,2-b]pyridazines |
| EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| CA2834901A1 (en) | 2011-05-06 | 2012-11-15 | Bayer Intellectual Property Gmbh | Substituted imidazopyridines and imidazopyridazines and the use thereof |
| JP6430383B2 (ja) | 2012-09-28 | 2018-11-28 | ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ | 選択的ｂｍｐ阻害剤としての縮合複素環化合物 |
| CN104768554B (zh) | 2012-11-07 | 2018-04-17 | 霍夫曼-拉罗奇有限公司 | 三唑并化合物 |
| WO2014160203A2 (en) * | 2013-03-14 | 2014-10-02 | The Brigham And Women's Hospital, Inc. | Bmp inhibitors and methods of use thereof |
| WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SG10202004618TA (en) | 2015-11-19 | 2020-06-29 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| MA44075A (fr) | 2015-12-17 | 2021-05-19 | Incyte Corp | Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1 |
| AU2016379372A1 (en) | 2015-12-22 | 2018-08-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| WO2017205464A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| HUE060256T2 (hu) | 2016-06-20 | 2023-02-28 | Incyte Corp | Heterociklusos vegyületek mint immunmodulátorok |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| DK3500571T3 (da) | 2016-08-17 | 2021-03-08 | Childrens Hospital Med Ct | Imidazo[1,2-a]pyridinforbindelser, sammensætninger omfattende disse, fremgangsmåder til behandling af sygdomme ved hjælp af disse og fremgangsmåder til fremstilling heraf |
| WO2018044783A1 (en) | 2016-08-29 | 2018-03-08 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20190218214A1 (en) * | 2016-09-14 | 2019-07-18 | Vanderbilt University | Inhibition of BMP Signaling Compounds, Compositions and Uses Thereof |
| MX2019002951A (es) | 2016-09-15 | 2019-09-11 | Armstrong World Ind Inc | Sistema de techo con movimiento aereo. |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| WO2018119263A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds derivatives as pd-l1 internalization inducers |
| JP7101678B2 (ja) | 2016-12-22 | 2022-07-15 | インサイト・コーポレイション | 免疫調節剤としての複素環式化合物 |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| US20180179202A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| LT3558990T (lt) | 2016-12-22 | 2022-12-27 | Incyte Corporation | Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai |
| WO2018136634A1 (en) | 2017-01-18 | 2018-07-26 | Vanderbilt University | Fused heterocyclic compounds as selective bmp inhibitors |
| WO2018165569A1 (en) | 2017-03-10 | 2018-09-13 | Rutgers, The State University Of New Jersey | Therapeutic compounds and methods |
| AU2018233367B2 (en) | 2017-03-16 | 2021-08-12 | Jiangsu Hengrui Medicine Co., Ltd. | Heteroaryl[4,3-c]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof |
| EP3601259B1 (en) | 2017-03-30 | 2022-02-23 | F. Hoffmann-La Roche AG | Isoquinolines as inhibitors of hpk1 |
| WO2019081353A1 (de) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | Substituierte imidazopyridinamide und ihre verwendung |
| TWI877770B (zh) | 2018-02-27 | 2025-03-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶 |
| CA3124088A1 (en) | 2018-12-20 | 2020-06-25 | Incyte Corporation | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 |
| CA3184811A1 (en) | 2020-06-12 | 2021-12-16 | Incyte Corporation | Imidazopyridazine compounds with activity as alk2 inhibitors |
-
2019
- 2019-12-19 CA CA3124088A patent/CA3124088A1/en active Pending
- 2019-12-19 MA MA054551A patent/MA54551A/fr unknown
- 2019-12-19 IL IL318278A patent/IL318278A/en unknown
- 2019-12-19 WO PCT/US2019/067403 patent/WO2020132197A1/en not_active Ceased
- 2019-12-19 CN CN202510176623.2A patent/CN120208959A/zh active Pending
- 2019-12-19 MX MX2021007426A patent/MX2021007426A/es unknown
- 2019-12-19 CR CR20210336A patent/CR20210336A/es unknown
- 2019-12-19 EP EP19848840.5A patent/EP3898627A1/en active Pending
- 2019-12-19 TW TW113128182A patent/TW202504901A/zh unknown
- 2019-12-19 JP JP2021535854A patent/JP7414827B2/ja active Active
- 2019-12-19 IL IL284139A patent/IL284139B2/en unknown
- 2019-12-19 BR BR112021011948-5A patent/BR112021011948A2/pt unknown
- 2019-12-19 TW TW108146732A patent/TWI852968B/zh active
- 2019-12-19 CN CN201980092367.1A patent/CN114787160B/zh active Active
- 2019-12-19 KR KR1020217022783A patent/KR20210116488A/ko active Pending
- 2019-12-19 PE PE2021001046A patent/PE20220277A1/es unknown
- 2019-12-19 AU AU2019401649A patent/AU2019401649B2/en active Active
- 2019-12-19 SG SG11202106582YA patent/SG11202106582YA/en unknown
- 2019-12-19 US US16/720,935 patent/US11459329B2/en active Active
-
2021
- 2021-06-18 PH PH12021551446A patent/PH12021551446A1/en unknown
- 2021-06-18 CL CL2021001656A patent/CL2021001656A1/es unknown
- 2021-06-21 EC ECSENADI202144843A patent/ECSP21044843A/es unknown
- 2021-06-21 CO CONC2021/0008117A patent/CO2021008117A2/es unknown
-
2022
- 2022-06-09 US US17/836,602 patent/US12030889B2/en active Active
-
2023
- 2023-12-28 JP JP2023222944A patent/JP7723068B2/ja active Active
-
2024
- 2024-05-22 US US18/671,477 patent/US20240309008A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI891666B (zh) | 作為ｆｇｆｒ抑制劑之雙環雜環 | |
| US12441731B2 (en) | Pyrazolopyrimidine compounds and uses thereof | |
| US11591329B2 (en) | Bicyclic heterocycles as FGFR inhibitors | |
| US12187725B2 (en) | Tricyclic urea compounds as JAK2 V617F inhibitors | |
| TWI852968B (zh) | 咪唑并嗒嗪及咪唑并吡啶化合物及其用途 | |
| TWI895442B (zh) | 咪唑并嗒嗪化合物及其用途 | |
| HK40057772A (en) | Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators | |
| HK40057772B (en) | Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators | |
| EA053050B1 (ru) | Трициклические соединения мочевины в качестве ингибиторов jak2 v617f |